Ellen M Lavoie Smith1, Tanima Banerjee, James J Yang, Celia M Bridges, Paola Alberti, Jeff A Sloan, Charles Loprinzi. 1. Author Affiliations: University of Michigan School of Nursing (Drs Smith and Yang and Ms Bridges); Institute for Healthcare Policy & Innovation, University of Michigan (Ms Banerjee), Ann Arbor; University of Milano-Bicocca (Dr Alberti), Italy; Alliance Statistics and Data Center (Dr Sloan), and Mayo Clinic (Dr Loprinzi), Rochester, Minnesota.
Abstract
BACKGROUND: No criterion-standard patient-reported outcome measure of chemotherapy-induced peripheral neuropathy (CIPN) exists. OBJECTIVES: The aims of this study were to reevaluate the sensitivity, reliability, and validity of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-CIPN (QLQ-CIPN20) measure and suggest possible revisions that could strengthen it. METHODS: Cross-sectional QLQ-CIPN20 data from 8 European countries (n = 271) were pooled with data from 4 North American multisite CIPN intervention trials (n = 884). The combined sample (N = 1155) included patients with varied cancer diagnoses who had received neurotoxic chemotherapy. Item score ranges, Cronbach's α, and exploratory factor analysis were used to evaluate sensitivity, internal consistency, and structural validity. RESULTS: Individual item mean scores ranged from 1.21 to 2.34 (SD range, 0.55-1.17). All item scores encompassed the entire 1 to 4 range. We recommend that 4 items be removed because of low item-item score correlations (r < 0.30). On the basis of the remaining 16 items, 88% of the variance was explained by 2 factors whose Cronbach's α coefficients were .90 and .85. However, items lacked conceptual alignment with previously published factor structures. CONCLUSION: Using a large, diverse sample of European and North American participants, the reduced 16-item QLQ-CIPN20 is sensitive and internally consistent. However, factor analysis results revealed an unstable factor structure. IMPLICATIONS FOR PRACTICE: The use of a reliable, valid, and sensitive criterion-standard QLQ-CIPN20 variant in clinical practice settings could improve function, quality of life, and CIPN symptom control by facilitating patient reporting and thereby clinician awareness of this underrecognized consequence of cancer therapy.
BACKGROUND: No criterion-standard patient-reported outcome measure of chemotherapy-induced peripheral neuropathy (CIPN) exists. OBJECTIVES: The aims of this study were to reevaluate the sensitivity, reliability, and validity of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-CIPN (QLQ-CIPN20) measure and suggest possible revisions that could strengthen it. METHODS: Cross-sectional QLQ-CIPN20 data from 8 European countries (n = 271) were pooled with data from 4 North American multisite CIPN intervention trials (n = 884). The combined sample (N = 1155) included patients with varied cancer diagnoses who had received neurotoxic chemotherapy. Item score ranges, Cronbach's α, and exploratory factor analysis were used to evaluate sensitivity, internal consistency, and structural validity. RESULTS: Individual item mean scores ranged from 1.21 to 2.34 (SD range, 0.55-1.17). All item scores encompassed the entire 1 to 4 range. We recommend that 4 items be removed because of low item-item score correlations (r < 0.30). On the basis of the remaining 16 items, 88% of the variance was explained by 2 factors whose Cronbach's α coefficients were .90 and .85. However, items lacked conceptual alignment with previously published factor structures. CONCLUSION: Using a large, diverse sample of European and North American participants, the reduced 16-item QLQ-CIPN20 is sensitive and internally consistent. However, factor analysis results revealed an unstable factor structure. IMPLICATIONS FOR PRACTICE: The use of a reliable, valid, and sensitive criterion-standard QLQ-CIPN20 variant in clinical practice settings could improve function, quality of life, and CIPN symptom control by facilitating patient reporting and thereby clinician awareness of this underrecognized consequence of cancer therapy.
Authors: Alexis D Leal; Rui Qin; Pamela J Atherton; Paul Haluska; Robert J Behrens; Charles H Tiber; Patanit Watanaboonyakhet; Matthias Weiss; Paul T Adams; Travis J Dockter; Charles L Loprinzi Journal: Cancer Date: 2014-03-11 Impact factor: 6.860
Authors: Kathleen A Griffith; Ingemar S J Merkies; Elizabeth E Hill; David R Cornblath Journal: J Peripher Nerv Syst Date: 2010-12 Impact factor: 3.494
Authors: P Alberti; E Rossi; D R Cornblath; I S J Merkies; T J Postma; B Frigeni; J Bruna; R Velasco; A A Argyriou; H P Kalofonos; D Psimaras; D Ricard; A Pace; E Galiè; C Briani; C Dalla Torre; C G Faber; R I Lalisang; W Boogerd; D Brandsma; S Koeppen; J Hense; D Storey; S Kerrigan; A Schenone; S Fabbri; M G Valsecchi; G Cavaletti Journal: Ann Oncol Date: 2013-11-19 Impact factor: 32.976
Authors: Debra L Barton; Edward J Wos; Rui Qin; Bassam I Mattar; Nathan Benjamin Green; Keith S Lanier; James Dewitt Bearden; John W Kugler; Kay L Hoff; Pavan S Reddy; Kendrith M Rowland; Mike Riepl; Bradley Christensen; Charles L Loprinzi Journal: Support Care Cancer Date: 2010-05-25 Impact factor: 3.603
Authors: Robert Knoerl; Evan Gray; Carrie Stricker; Sandra A Mitchell; Kelsey Kippe; Gloria Smith; William N Dudley; Ellen M Lavoie Smith Journal: Support Care Cancer Date: 2017-06-02 Impact factor: 3.603
Authors: Charles L Loprinzi; Rui Qin; Shaker R Dakhil; Louis Fehrenbacher; Kathleen A Flynn; Pamela Atherton; Drew Seisler; Rubina Qamar; Grant C Lewis; Axel Grothey Journal: J Clin Oncol Date: 2013-12-02 Impact factor: 44.544
Authors: E A Calhoun; E E Welshman; C-H Chang; J R Lurain; D A Fishman; T L Hunt; D Cella Journal: Int J Gynecol Cancer Date: 2003 Nov-Dec Impact factor: 3.437
Authors: G Cavaletti; D R Cornblath; I S J Merkies; T J Postma; E Rossi; B Frigeni; P Alberti; J Bruna; R Velasco; A A Argyriou; H P Kalofonos; D Psimaras; D Ricard; A Pace; E Galiè; C Briani; C Dalla Torre; C G Faber; R I Lalisang; W Boogerd; D Brandsma; S Koeppen; J Hense; D Storey; S Kerrigan; A Schenone; S Fabbri; M G Valsecchi; A Mazzeo; A Pace; A Pessino; A Schenone; A Toscano; A A Argyriou; B Brouwer; B Frigeni; B Piras; C Briani; C Dalla Torre; C Dominguez Gonzalez; C G Faber; C Tomasello; D Binda; D Brandsma; D Cortinovis; D Psimaras; D Ricard; D Storey; D R Cornblath; E Galiè; E Lindeck Pozza; E Rossi; E K Vanhoutte; F Lanzani; F Pastorelli; G Altavilla; G Cavaletti; G Granata; H P Kalofonos; I Ghignotti; I S J Merkies; J Bruna; J Hense; J J Heimans; L Mattavelli; L Padua; L Reni; M Bakkers; M Boogerd; M Campagnolo; M Cazzaniga; M Eurelings; M Leandri; M Lucchetta; M Penas Prado; M Russo; M G Valsecchi; M L Piatti; P Alberti; P Bidoli; R Grant; R Plasmati; R Velasco; R I Lalisang; R J Meijer; S Fabbri; S G Dorsey; S Galimberti; S Kerrigan; S Koeppen; T J Postma; W Boogerd; W Grisold Journal: Ann Oncol Date: 2012-08-21 Impact factor: 32.976
Authors: Michael D Stubblefield; Harold J Burstein; Allen W Burton; Christian M Custodio; Gary E Deng; Maria Ho; Larry Junck; G Stephen Morris; Judith A Paice; Sudhakar Tummala; Jamie H Von Roenn Journal: J Natl Compr Canc Netw Date: 2009-09 Impact factor: 11.908
Authors: Ellen M Lavoie Smith; Noah Zanville; Grace Kanzawa-Lee; Clare Donohoe; Celia Bridges; Charles Loprinzi; Jennifer Le-Rademacher; James J Yang Journal: Support Care Cancer Date: 2018-11-20 Impact factor: 3.603
Authors: Ciao-Sin Chen; Ellen M Lavoie Smith; Kathleen A Stringer; N Lynn Henry; Daniel L Hertz Journal: Breast Cancer Res Treat Date: 2022-06-28 Impact factor: 4.624
Authors: Cynthia S Bonhof; Daniëlle L van de Graaf; Dareczka K Wasowicz; Gerard Vreugdenhil; Floortje Mols Journal: Support Care Cancer Date: 2022-03-18 Impact factor: 3.359
Authors: Fiona Yeo; Chiu Chin Ng; Kiley W J Loh; Alex Molassiotis; Hui Lin Cheng; Joseph S K Au; Kwun To Leung; Yu Chung Li; Kam-Hung Wong; Lorna Suen; Choi Wan Chan; Janelle Yorke; Carole Farrell; Aishwarya Bandla; Emily Ang; Violeta Lopez; Raghav Sundar; Alexandre Chan Journal: Support Care Cancer Date: 2019-04-10 Impact factor: 3.603
Authors: Marie Selvy; Nicolas Kerckhove; Bruno Pereira; Fantine Barreau; Daniel Nguyen; Jérôme Busserolles; Fabrice Giraudet; Aurélie Cabrespine; Carine Chaleteix; Martin Soubrier; Jacques-Olivier Bay; Richard Lemal; David Balayssac Journal: Front Pharmacol Date: 2021-04-22 Impact factor: 5.810
Authors: Eiman Y Ibrahim; Saira Munshani; Ilaria Domenicano; Rozalyn Rodwin; Richard J Nowak; Lajos Pusztai; Maryam Lustberg; Barbara E Ehrlich Journal: PLoS One Date: 2022-10-07 Impact factor: 3.752
Authors: Tiffany Li; Susanna B Park; Eva Battaglini; Madeleine T King; Matthew C Kiernan; David Goldstein; Claudia Rutherford Journal: Qual Life Res Date: 2022-05-21 Impact factor: 3.440
Authors: Ellen M Lavoie Smith; Robert Knoerl; James J Yang; Grace Kanzawa-Lee; Deborah Lee; Celia M Bridges Journal: Cancer Control Date: 2018 Jan-Mar Impact factor: 3.302